

Wieslab Request Form – Monitoring of Biopharmaceuticals



ORDERING INFORMATION

Requesting Clinic – required Postal address for test results	Invoice Address Postal or email address for invoice. Only doctors, labs, or hospitals can be invoiced
Ref. Number or Cost Center	

REQUESTING DOCTOR

Name	
Email	Phone
Date of last drug administration/Other comments	

TERMS & CONDITIONS

View our terms and conditions: svarlifescience.com/wieslab-terms

PATIENT DATA

Full Name	Gender <input type="checkbox"/> Woman <input type="checkbox"/> Man <input type="checkbox"/> Other
Birth Date, Identity Number	Sampling Date

The health care provider submitting the sample(s) and this Request Form hereby confirms that the patient (or the patient's guardian or trustee, if applicable) has been informed about the [Terms and Conditions](#) regarding sample handling and storage.

- No, the patient does not consent to save the sample.
 The patient is currently unable to consent to the retention of the sample(s).

INSTRUCTIONS

C = Concentration of biopharmaceutical.
R = Concentration and ADA testing.
A = ADA testing.

- The sample should be drawn at trough value, just before the next drug administration. Trough value is the minimal drug concentration at steady state and when the variations of drug levels in serum are the lowest.
- Presence of drug in the test sample may prevent the detection of ADA (Anti-Drug Antibodies).

Send Frozen **Send Cold** **Can be sent at room temperature**

Comprehensive instructions available at svarlifescience.com/sampling-instructions

SHIPPING

Send to
Wieslab AB
Lundavägen 151, 212 24 Malmö, Sweden

CONTACT

Phone +46 (0)40-53 76 60
Email: diagnostic.services@svarlifescience.com

Updated: 2024-07-02

Tests

B/T CELL INHIBITORS

<input type="checkbox"/> C 615 Abatacept At least 0.7 mL serum per sample.
<input type="checkbox"/> C 603 Rituximab <input type="checkbox"/> R At least 0.7 mL serum per sample.

COMPLEMENT INHIBITORS

<input type="checkbox"/> C 613 Eculizumab At least 0.7 mL serum per sample.

CYTOKINE INHIBITORS

<input type="checkbox"/> C 607 Tocilizumab <input type="checkbox"/> R At least 0.7 mL serum per sample.
<input type="checkbox"/> C 605 Ustekinumab <input type="checkbox"/> R At least 0.7 mL serum per sample. ADA testing performed only if biopharmaceutical concentration is low.

INTEGRIN INHIBITORS

<input type="checkbox"/> C 136 Natalizumab <input type="checkbox"/> R At least 0.7 mL serum per sample.
<input type="checkbox"/> C 138 Vedolizumab <input type="checkbox"/> R At least 0.7 mL serum per sample. ADA testing performed only if biopharmaceutical concentration is low.

TNF-ALPHA INHIBITORS

<input type="checkbox"/> C 126 Adalimumab <input type="checkbox"/> R At least 0.7 mL serum per sample. ADA testing performed only if biopharmaceutical concentration is low.
<input type="checkbox"/> C 132 Certolizumab At least 0.5 mL serum per sample.
<input type="checkbox"/> C 128 Etanercept At least 0.5 mL serum per sample.
<input type="checkbox"/> C 130 Golimumab <input type="checkbox"/> R At least 0.7 mL serum per sample. ADA testing performed only if biopharmaceutical concentration is low.
<input type="checkbox"/> C 124 Infliximab <input type="checkbox"/> R At least 0.7 mL serum per sample. ADA testing performed only if biopharmaceutical concentration is low.

OTHER

<input type="checkbox"/> A 105 Erythropoietin At least 1 mL serum per sample.

Have you seen our other request forms? We have request forms for Neurology, Autoimmunity, and Monitoring of Biopharmaceuticals: wieslab.se/remisser